1. d'Amore F, Brincker H, Grønbaek K, et al. 1994; Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 12:1673–1684. DOI:
10.1200/JCO.1994.12.8.1673. PMID:
8040680.
2. Ko YH, Kim CW, Park CS, et al. 1998; REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 83:806–812. DOI:
10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V. PMID:
9708949.
3. Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J. 2006; Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 101:2826–2832. DOI:
10.1111/j.1572-0241.2006.00854.x. PMID:
17026561.
Article
5. Koch P, del Valle F, Berdel WE, et al. 2001; Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 19:3861–3873. DOI:
10.1200/JCO.2001.19.18.3861. PMID:
11559724.
Article
6. Ruskoné-Fourmestraux A, Aegerter P, Delmer A, Brousse N, Galian A, Rambaud JC. 1993; Primary digestive tract lymphoma: a prospective multicentric study of 91 patients. Groupe d'Etude des Lymphomes Digestifs. Gastroenterology. 105:1662–1671. DOI:
10.1016/0016-5085(93)91061-L.
7. Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. 2000; Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology. 119:1191–1202. DOI:
10.1053/gast.2000.19579. PMID:
11054376.
8. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. 2003; Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 97:2462–2473. DOI:
10.1002/cncr.11415. PMID:
12733145.
9. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. 2011; EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 60:747–758. DOI:
10.1136/gut.2010.224949. PMID:
21317175.
Article
10. Zucca E. ESMO Guidelines Working Group. 2007; Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 18(Suppl 2):ii59–ii60. DOI:
10.1093/annonc/mdm039. PMID:
17491050.
Article
11. Matysiak-Budnik T, Jamet P, Fabiani B, et al. 2013; Primary intestinal B-cell lymphoma: a prospective multicentre clinical study of 91 cases. Dig Liver Dis. 45:947–952. DOI:
10.1016/j.dld.2013.05.008. PMID:
23816692.
Article
12. Kim SJ, Choi CW, Mun YC, et al. 2011; Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer. 11:321. DOI:
10.1186/1471-2407-11-321. PMID:
21798075. PMCID:
PMC3160411.
Article
13. Gurney KA, Cartwright RA, Gilman EA. 1999; Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry. Br J Cancer. 79:1929–1934. DOI:
10.1038/sj.bjc.6690307. PMID:
10206316. PMCID:
PMC2362786.
Article
14. Kim SJ, Kang HJ, Kim JS, et al. 2011; Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 117:1958–1965. DOI:
10.1182/blood-2010-06-288480. PMID:
21148334.
Article
15. Wang M, Ma S, Shi W, Zhang Y, Luo S, Hu Y. 2021; Surgery shows survival benefit in patients with primary intestinal diffuse large B-cell lymphoma: a population-based study. Cancer Med. 10:3474–3485. DOI:
10.1002/cam4.3882. PMID:
33931950. PMCID:
PMC8124121.
Article
17. Li B, Shi YK, He XH, et al. 2008; Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol. 87:375–381. DOI:
10.1007/s12185-008-0068-5. PMID:
18409078.
Article
20. Daum S, Ullrich R, Heise W, et al. 2003; Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol. 21:2740–2746. DOI:
10.1200/JCO.2003.06.026. PMID:
12860953.
Article
21. Kodama T, Ohshima K, Nomura K, et al. 2005; Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology. 47:467–478. DOI:
10.1111/j.1365-2559.2005.02225.x. PMID:
16241994.
Article
22. Salar A, Juanpere N, Bellosillo B, et al. 2006; Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 30:1274–1280. DOI:
10.1097/01.pas.0000208899.15859.cb. PMID:
17001159.
Article
24. Troppan KT, Melchardt T, Deutsch A, et al. 2015; The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol. 95:538–544. DOI:
10.1111/ejh.12529. PMID:
25677782.
Article
25. Tisi MC, Bozzoli V, Giachelia M, et al. 2014; Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma. 55:270–275. DOI:
10.3109/10428194.2013.802314. PMID:
23647063.
Article
26. Giachelia M, Voso MT, Tisi MC, et al. 2012; Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 53:411–416. DOI:
10.3109/10428194.2011.621566. PMID:
21902578.
27. Suzuki K, Terui Y, Nishimura N, et al. 2013; Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma. Jpn J Clin Oncol. 43:37–44. DOI:
10.1093/jjco/hys194. PMID:
23166385.
Article
28. Hong J, Woo HS, Kim H, et al. 2014; Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci. 105:1569–1575. DOI:
10.1111/cas.12544. PMID:
25263825. PMCID:
PMC4317957.
29. Gobbi PG, Ghirardelli ML, Cavalli C, et al. 2000; The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Haematologica. 85:372–380. PMID:
10756362.
30. Ibrahim EM, Ezzat AA, El-Weshi AN, et al. 2001; Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 12:53–58. DOI:
10.1023/A:1008389001990. PMID:
11249049.
Article
31. Zinzani PL, Magagnoli M, Pagliani G, et al. 1997; Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica. 82:305–308. PMID:
9234576.
32. Kobayashi H, Nagai T, Omine K, et al. 2013; Clinical outcome of non-surgical treatment for primary small intestinal lymphoma diagnosed with double-balloon endoscopy. Leuk Lymphoma. 54:731–736. DOI:
10.3109/10428194.2012.725850. PMID:
22946663.
Article
33. Shawky H, Tawfik H. 2008; Primary gastrointestinal non-Hodgkin's lymphoma: a retrospective study with emphasis on prognostic factors and treatment outcome. J Egypt Natl Canc Inst. 20:330–341.
34. Lee HS, Park LC, Lee EM, et al. 2014; Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma. Am J Clin Oncol. 37:182–187. DOI:
10.1097/COC.0b013e318271b125. PMID:
23211226.
Article